One shot showdown: can a new HPV vaccine match the gold standard?
NCT ID NCT07256912
First seen Jan 05, 2026 · Last updated May 13, 2026 · Updated 19 times
Summary
This study tests whether a single dose of the CERVAVAC HPV vaccine works as well as a single dose of the Gardasil vaccine. About 1,266 girls and boys aged 9 to 20 in Zambia will receive one shot and be followed for two years. Researchers will compare immune responses to see if CERVAVAC is a good alternative for preventing cervical cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER PREVENTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chipata and Matero First Level Hospitals
Lusaka, Zambia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.